News

AstraZeneca and Daiichi Sankyo’ s ENHERTU ® has been approved in the US for the treatment of adult patients with unresectable or metastatic hormone receptor- positive, HER2-low or HER2-ultralow ...
With ENHERTU (fam-trastuzumab deruxtecan-nxki), a HER2-directed antibody drug conjugate (ADC), AstraZeneca and Daiichi Sankyo are aiming to improve outcomes in previously treated HER2-positive and ...
AstraZeneca (AZN) announced Enhertu in combination with pertuzumab has been granted Breakthrough Therapy Designation in the U.S. for the first-line treatment of adult patients with unresectable or ...
ENHERTU is a specifically engineered HER2-directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo and being jointly developed and commercialized by AstraZeneca and Daiichi Sankyo.
Susan Galbraith, Executive Vice President of Oncology Haematology R&D at AstraZeneca, emphasized the study’s importance, stating, “Bringing ENHERTU earlier in the treatment of HER2-positive ...
ENHERTU is a specifically engineered HER2-directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo and being jointly developed and commercialized by AstraZeneca and Daiichi Sankyo.
AstraZeneca Plc and Daiichi Sankyo Co.’s Enhertu delayed the advance of a common type of breast cancer by more than a year in a large study, a result that may lead to expanded use of the medicine.
Enhertu reduced the risk of disease progression or death by 36%, with a median PFS of 13.2 months versus 8.1 months for chemotherapy. The trial showed an ORR of 62.6% for Enhertu compared to 34.4% ...
AstraZeneca is jointly developing and commercializing ENHERTU, which is the drug being evaluated in the DESTINY-Endometrial01 phase 3 trial, with Daiichi Sankyo under a global collaboration.
AstraZeneca scrapped plans for a £450 million UK vaccine plant after rejecting a £78 million ... FDA Approves AstraZeneca, Daiichi Sankyo's Enhertu For Certain Type Of Breast Cancer ...
Daiichi Sankyo (DSNKY) and AstraZeneca’s (AZN) Enhertu has been approved in the European Union as a monotherapy for the treatment of adult patients with unresectable or metastatic hormone ...
Astrazeneca Says Enhertu Recommended In EU For Her2-Mutant NSCLC. By Reuters. September 15, 2023 2:10 PM UTC Updated September 15, 2023 Sept 15 (Reuters) - AstraZeneca PLC: ...